Blastic plasmacytoid dendritic cell neoplasm

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86870C86.4
Who is this for?
Show terms as
1FDA treatments5Active trials41Specialists8Treatment centers1Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

BPDCN
Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
Dec 2025Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

French Innovative Leukemia Organisation — PHASE2

TrialNOT YET RECRUITING
Aug 2023Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Chongqing Precision Biotech Co., Ltd — PHASE1, PHASE2

TrialRECRUITING
Jul 2022Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Immune Oncology Research Institute

TrialRECRUITING
May 2020Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center — PHASE2

TrialRECRUITING
Dec 2018

ELZONRIS: FDA approved

ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

FDAcompleted
Jan 2018Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

AbbVie — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Jun 2017SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dana-Farber Cancer Institute — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

ELZONRIS

Tagraxofusp-erzs· Stemline Therapeutics, Inc.■ Boxed WarningOrphan Drug

ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

View Details →FDA Label ↗Copay Card ↗Patient Assistance ↗

Clinical Trials

5 recruitingView all trials with filters →
Phase 21 trial
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2
Actively Recruiting
PI: Naveen Pemmaraju (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 11 trial
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1
Actively Recruiting
PI: Andrew Lane, MD, PhD (Dana-Farber Cancer Institute) · Sites: Duarte, California; Boston, Massachusetts +1 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other1 trial
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Actively Recruiting
PI: Astghik Voskanyan, MD (Immune Oncology Research Institute, Yerevan, Armen) · Sites: Miami, Florida; Tampa, Florida +18 more
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 41View all specialists →
JM
Jia Wei, M.D
Specialist
PI on 1 active trial
LB
Lihua E. Budde
DUARTE, CA
Specialist
PI on 1 active trial
EK
Elizabeth Krakow
DECATUR, GA
Specialist
PI on 2 active trials
RM
Raman Garcha, MD
Specialist
PI on 1 active trial
SP
Seokjin Kim, M.D., PhD
Specialist
PI on 1 active trial
NP
Naveen Pemmaraju
HOUSTON, TX
Specialist
PI on 3 active trials10 Blastic plasmacytoid dendritic cell neoplasm publications
NM
Naval Daver, MD
HOUSTON, TX
Specialist
PI on 8 active trials
DM
David Maloney
Specialist
PI on 11 active trials
AM
Arthur E. Frankel, MD
ABINGTON, PA
Specialist
PI on 1 active trial1 Blastic plasmacytoid dendritic cell neoplasm publication
MF
Maryam Fouladi
COLUMBUS, OH
Specialist
PI on 7 active trials2 Blastic plasmacytoid dendritic cell neoplasm publications
MB
Marie Bleakley
SEATTLE, WA
Specialist
PI on 4 active trials
AM
Astghik Voskanyan, MD
Specialist
PI on 1 active trial1 Blastic plasmacytoid dendritic cell neoplasm publication
AD
Ann Dahlberg
MILWAUKEE, WI
Specialist
PI on 2 active trials
DM
Denise Casey, M.D.
ROCHESTER, NY
Specialist
PI on 2 active trials
SM
Swati Naik, MD
MEMPHIS, TN
Specialist
PI on 1 active trial
GD
Gevorg Tamamyan, MD, PhD, DSc
Specialist
PI on 2 active trials
JM
Jithma P. Abeykoon, MD
ROCHESTER, MN
Specialist
PI on 1 active trial
PP
Petr Lesný, MD, PhD
Specialist
PI on 1 active trial
AP
Andrew Lane, MD, PhD
Specialist
PI on 1 active trial
JP
Jan Vydra, MD, PhD
Specialist
PI on 1 active trial
PM
Paulina Velasquez, MD
IRVINE, CA
Specialist
PI on 1 active trial
AM
Andrew Lane, MD
Specialist
PI on 1 active trial1 Blastic plasmacytoid dendritic cell neoplasm publication
IA
Ibrahim T Aldoss
DUARTE, CA
Specialist
PI on 1 active trial
TW
Thomas Witzig
ROCHESTER, MN
Specialist
PI on 5 active trials
RM
Rochelle Emery, MD
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
ELZONRIS(Tagraxofusp-erzs)— Stemline Therapeutics, Inc.

Travel Grants

No travel grants are currently matched to Blastic plasmacytoid dendritic cell neoplasm.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Blastic plasmacytoid dendritic cell neoplasmForum →

No community posts yet. Be the first to share your experience with Blastic plasmacytoid dendritic cell neoplasm.

Start the conversation →

Latest news about Blastic plasmacytoid dendritic cell neoplasm

Disease timeline:

New recruiting trial: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A new clinical trial is recruiting patients for Blastic plasmacytoid dendritic cell neoplasm

New recruiting trial: Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

A new clinical trial is recruiting patients for Blastic plasmacytoid dendritic cell neoplasm

New recruiting trial: Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

A new clinical trial is recruiting patients for Blastic plasmacytoid dendritic cell neoplasm

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Blastic plasmacytoid dendritic cell neoplasm

Are there clinical trials for Blastic plasmacytoid dendritic cell neoplasm?

Yes — 5 recruiting clinical trials are currently listed for Blastic plasmacytoid dendritic cell neoplasm on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Blastic plasmacytoid dendritic cell neoplasm?

25 specialists and care centers treating Blastic plasmacytoid dendritic cell neoplasm are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Blastic plasmacytoid dendritic cell neoplasm?

1 patient support program are currently tracked on UniteRare for Blastic plasmacytoid dendritic cell neoplasm. See the treatments and support programs sections for copay assistance, eligibility, and contact details.